Robust clinical trials [50,53] demonstrated the efficacy and safety of the poly (ADP-ribose) polymerase inhibitors (PARPis) in patients with HER2-negative advanced breast cancer and pathogenic germline BRCA1/2 mutations (gBRCAm). This evidence concerns the gene ERBB2 and breast carcinoma.